Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03678753
Registration number
NCT03678753
Ethics application status
Date submitted
18/09/2018
Date registered
20/09/2018
Date last updated
5/04/2024
Titles & IDs
Public title
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures
Query!
Secondary ID [1]
0
0
YKP3089C025
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Primary Generalized Epilepsy
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Epilepsy
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cenobamate
Treatment: Drugs - Placebo
Experimental: Cenobamate - Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
Placebo Comparator: Placebo - Matching placebo
Treatment: Drugs: Cenobamate
12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
Treatment: Drugs: Placebo
Matching Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Seizure Diary
Query!
Assessment method [1]
0
0
Daily seizure diary that contains type and frequency of seizures
Query!
Timepoint [1]
0
0
28 Days
Query!
Eligibility
Key inclusion criteria
1. Subject is male or female and aged =12 years.
2. Written informed consent signed by the subject or legal guardian, or legally
authorized representative (LAR), prior to entering the study, in accordance with the
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)
guidelines. Age- appropriate assent will be obtained for adolescents. If the written
informed consent is provided by the legal guardian because the subject is unable to do
so, a written or verbal assent from the subject must also be obtained. As required by
country-specific regulations, only the subject may sign the Informed Consent Form
(ICF) in accordance with ICH guidelines.
3. Female subjects of childbearing potential are willing to use an acceptable form of
birth control
4. Subject has a clinical diagnosis of PGTC seizures (with or without other subtypes of
generalized seizures) in the setting of idiopathic generalized epilepsy.
5. Subject experiences at least 5 PGTC seizures in 12 weeks during the Pre-Randomization
Period.
6. Subject has had a routine electroencephalogram (EEG) within 5 years prior to Visit1
(Screening/Baseline) or during the Pre-Randomization Period with
electroencephalographic features consistent with idiopathic generalized epilepsy;
other concomitant anomalies must be explained by adequate past medical history.
7. Subject has undergone computed tomography (CT) or magnetic resonance imaging (MRI)
within 10 years prior to Visit 1 (Screening/Baseline) or during the Pre-Randomization
Period that ruled out a progressive cause of epilepsy.
8. Subject is currently receiving 1 to a maximum of 3 concomitant AEDs with fixed dosing
regimens for a minimum of 30 days prior to Visit 1 (Screening/Baseline).
1. Benzodiazepines (except diazepam, see
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criterion No.7) taken at least
once per week during the 30 days prior to Visit 1 (Screening/Baseline) for
epilepsy, anxiety, or sleep disorder will be counted as 1 AED and the dosage must
be continued unchanged throughout the study. Therefore, only a maximum of 2
additional approved AEDs will be allowed. (See Exclusion Criterion No. 10 for
intermittent benzodiazepine rescue parameters.)
2. Subjects receiving felbamate as a concomitant AED must meet the following
criteria: i. Have a 2-year history of felbamate use and a history of a fixed
dosing regimen for a minimum of 60 days prior to Visit 1 (Screening/Baseline).
ii. No prior or known history of hepatotoxicity or hematologic disorder due to
felbamate.
9. Subject with an implanted vagal nerve or deep brain stimulator will be allowed if the
stimulator was implanted at least 5 months prior to Visit 1 (Screening/Baseline) and
the stimulator parameters are not changed for 30 days prior to Visit 1 and for the
duration of the study.
10. Subject taking a ketogenic diet will be allowed as long as the diet has been stable
for at least 3 months prior to Visit 1 (Screening/Baseline) and will remain stable for
the duration of the study.
1. Female subjects who are pregnant (or planning to become pregnant during the study),
lactating, or breast-feeding.
2. Subject has a history o f status epilepticus that required hospitalization within 12
months prior to Visit 1 (Screening/Baseline).
3. Subject has PGTC seizure clusters where individual seizures cannot be counted or
classified.
4. Subject has a history of non-epileptic psychogenic seizures.
5. Subject has a concomitant diagnosis of Partial Onset Seizures (POS).
6. Subject has a clinical diagnosis of Lennox-Gastaut syndrome.
7. Subject is currently taking (within the 30 days prior to Visit 1 [Screening/Baseline])
any of the following medications: diazepam (for any reason other than as intermittent
benzodiazepine rescue medication), phenytoin, mephenytoin, fosphenytoin,
phenobarbital, primidone, ethotoin, clopidogrel, fluvoxamine, amitriptyline,
clomipramine, bupropion, methadone, ifosfamide, cyclophosphamide, or efavirenz.
8. Subject has participated in previous cenobamate clinical studies.
9. Subject has a history of vigabatrin use within 5months prior to Visit 1
(Screening/Baseline), or the subject plans to begin treatment with vigabatrin during
the study.
a) A subject with a history of vigabatrin use that ended more than 5 months prior to
Visit1 may be enrolled after documented evidence of no vigabatrin-associated
clinically significant abnormality in an automated visual perimetry test.
10. Subject has a history of intermittent use of rescue benzodiazepines (i.e., 1 to 2
doses over a 24-hour period is considered a 1-time rescue) 4 or more times within the
30 days prior to Visit 1 (Screening/Baseline).
11. Subject has received an investigational drug or device within 30 days prior to Visit 1
(Screening/Baseline).
12. Subject has a history of drug or alcohol dependency or abuse within 2 years prior to
Visit 1 (Screening/Baseline).
13. Subject tests positive, via urine drug screen at Visit 1 (Screening/Baseline), for
illicit drugs not legalized in your region/state, or for a drug that has not been
prescribed (e.g., certain opiates).
14. Subject has a history of any serious drug-induced hypersensitivity reaction
(including, but not limited to, Stevens Johnson syndrome, toxic epidermal necrolysis,
or DRESS) or any drug-related rash requiring hospitalization.
15. History of AED-associated rash that involved conjunctiva or mucosae.
16. History of more than one non-serious drug-related hypersensitivity reaction that
required discontinuation of the medication.
17. Subject has evidence of clinically significant abnormalities or disease (e.g.,
psychiatric, cardiac, respiratory, gastrointestinal, hepatic [aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) more than 2 times the upper
limit of normal (ULN), or total or direct bilirubin not more than ULN], or renal
disease) that, in the opinion of the Principal Investigator, could affect the
subject's safety or conduct of the study.
18. Presence of congenital short QT syndrome or relevant replicated change in QT/QTc
interval less than 340 msec on ECG.
19. Subject has any significant active Central Nervous System (CNS) infection,
demyelinating disease, degenerative neurologic disease or any CNS disease deemed to be
progressive during the course of the study that may confound the interpretation of the
study results.
20. Subject has a creatinine clearance less than 50 mL/min, as calculated by
Cockcroft-Gault equation.
21. Subject has an absolute neutrophil count less than 1500/µL.
22. Subject has platelet count lower than 80,000/µL in subjects treated with valproate.
23. Subject has a history of positive antibody/antigen test for hepatitis A, hepatitis B,
hepatitis C, or HIV.
24. Subject has any suicidal ideation (with intent with or without a plan) at Visit 1
(Screening/Baseline) or Visit 4 (Randomization) (i.e., answering YES to Question 4
and/or Question 5 on the Suicidal Ideation section of the C-SSRS).
25. Subject has more than 1 lifetime suicide attempt.
26. Subject is a staff member or immediate family member of study staff.
27. Previous exposure to cenobamate or sensitivity/allergy to components of the oral
suspension.
Any potential exception to the inclusion as well as exclusion criteria allowing de minimis
(clinically trivial and meaningless) variations must be approved by the Medical Monitor.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/09/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
19/07/2024
Query!
Actual
Query!
Sample size
Target
170
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [2]
0
0
Children's Health Queensland Hospital - South Brisbane
Query!
Recruitment postcode(s) [1]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Hawaii
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Utah
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Veliko Tarnovo
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Blagoevgrad
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Ruse
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Sofia
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Varna
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Brno
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Hradec Králové
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Ostrava-Poruba
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Ostrava-Vitkovice
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Praha 6
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Rychnov Nad Knežnou
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Zlín
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Berlin
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Jena
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Kiel
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Radeberg
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Debrecen
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Hodmezovasarhely
Query!
Country [47]
0
0
Korea, Republic of
Query!
State/province [47]
0
0
Chungcheongbuk-Do
Query!
Country [48]
0
0
Korea, Republic of
Query!
State/province [48]
0
0
Gyeonggi-do
Query!
Country [49]
0
0
Korea, Republic of
Query!
State/province [49]
0
0
Gyeonggi-Do
Query!
Country [50]
0
0
Korea, Republic of
Query!
State/province [50]
0
0
Daegu
Query!
Country [51]
0
0
Korea, Republic of
Query!
State/province [51]
0
0
Suwon
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Dolnoslaskie
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Iodzkie
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Lubelskie
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Malopolskie
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Mazowieckie
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Silesia
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Slaskie
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Swietokrzyskie
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warminsko-Mazurskie
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Wielkopolskie
Query!
Country [62]
0
0
Slovakia
Query!
State/province [62]
0
0
Trencin
Query!
Country [63]
0
0
Slovakia
Query!
State/province [63]
0
0
Banská Bystrica
Query!
Country [64]
0
0
Slovakia
Query!
State/province [64]
0
0
Bardejov
Query!
Country [65]
0
0
Slovakia
Query!
State/province [65]
0
0
Bratislava
Query!
Country [66]
0
0
Slovakia
Query!
State/province [66]
0
0
Dolný Kubín
Query!
Country [67]
0
0
Slovakia
Query!
State/province [67]
0
0
Krompachy
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Madrid
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Malaga
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Valencia
Query!
Country [71]
0
0
Ukraine
Query!
State/province [71]
0
0
Dnipropetrovsk
Query!
Country [72]
0
0
Ukraine
Query!
State/province [72]
0
0
Dnipro
Query!
Country [73]
0
0
Ukraine
Query!
State/province [73]
0
0
Kyiv
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Odessa
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Zakarpattia
Query!
Country [76]
0
0
Ukraine
Query!
State/province [76]
0
0
Zaporizhzhya
Query!
Country [77]
0
0
Ukraine
Query!
State/province [77]
0
0
Ivano-Frankivsk
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Kharkiv
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Lviv
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Poltava
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Ternopil
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Vinnytsya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
SK Life Science, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial is intended to study the safety and effectiveness of an new anti-epileptic drug
(AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects, adults and
adolescents, will continue to take their usual AEDs and receive either cenobamate or placebo.
Subjects will have a 50% chance or receiving cenobamate or placebo (sugar pill). Subjects
will initially receive 12.5 mg of cenobamate or placebo (study drug) and increase the dose
every two weeks until they reach a target dose of 200 mg. Subjects will take study drug at
approximately the same time in the morning (once a day) with or without food. If tolerability
issues arise, dosing can be changed to evening. Also, once a subject reaches 200 mg, the dose
can be decreased one time to 150 mg, if necessary. The treatment period is 22 weeks and there
is a 3 week follow up period, which includes a one week decrease in study drug to 100 mg
prior to stopping. Adolescents will follow the same every two week regimen and receive
cenobamate as an oral suspension based on weight. Subjects who complete may be eligible for
an extension study and will not have to complete the follow up period. Subjects will track
their seizure types and frequency in a diary throughout the study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03678753
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Sunita Misra, MD
Query!
Address
0
0
SK Life Science, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Sunita Misra, MD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-402-835-5977
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03678753
Download to PDF